Bioinformatics Partnering Terms & Agreements -





Publication date: September 2013 | Version: 4 | Pages: 1,268

 

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies. 

  

  • Trends in bioinformatics partnering deals 
  • Deal terms analysis 
  • Partnering agreement structure 
  • Partnering contract documents 
  • Top deals by value 
  • Most active dealmakers 
  • Average deal terms for bioinformatics 

  

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies. 

  

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

  

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors. 

  

Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine. 

  

Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes. 

  

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. 

  

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2007, including financial terms where available, including over 1700 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. 

  

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. 

                     

Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. 

  

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. 

  

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. 

  

Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

  

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z , deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

  

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007. 

                                                   

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products. 

  

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits: 

  

• In-depth understanding of bioinformatics deal trends since 2007 

• Access to headline, upfront, milestone and royalty data 

• Analysis of the structure of bioinformatics agreements with numerous real life case studies 

•Comprehensive access to over 1700  bioinformatics deals entered into by the world’s biopharma companies 

• Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies 

• Insight into the terms included in a bioinformatics agreement, together with real world clause examples 

• Understand the key deal terms companies have agreed in previous deals 

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies 

  

Report scope 

  

Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bioinformatics trends and structure of deals entered into by leading companies worldwide. 

  

Bioinformatics Partnering Terms and Agreements includes: 

o Trends in bioinformatics dealmaking in the biopharma industry since 2007 

o Analysis of bioinformatics deal structure 

o Access to headline, upfront, milestone and royalty data 

o Case studies of real-life bioinformatics deals 

o Access to over 1700 bioinformatics deal documents 

o Access to contract documents where available 

o The leading bioinformatics deals by value since 2007 

o Most active bioinformatics dealmakers since 2007 

o The leading bioinformatics partnering resources In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by: 

o Company A-Z 

o Headline value 

o Stage of development at signing 

o Deal component type 

o Therapy target 

  

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Bioinformatics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of the following: 

 

o What are the precise bioinformatics rights granted or optioned? 

o What is actually granted by the agreement to the partner company? 

o What exclusivity is granted? 

o What is the payment structure for the deal? 

o How are sales and payments audited? 

o What is the deal term? 

o How are the key terms of the agreement defined? 

o How are IPRs handled and owned? 

o Who is responsible for commercialization? 

o Who is responsible for development, supply, and manufacture? 

o How is confidentiality and publication managed? o How are disputes to be resolved? 

o Under what conditions can the deal be terminated? o What happens when there is a change of ownership? 

o What sublicensing and subcontracting provisions have been agreed? o Which boilerplate clauses does the company insist upon? 

o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? 

o Which jurisdiction does the company insist upon for agreement law? 

Executive Summary 

 

Chapter 1 – Introduction 

 

Chapter 2 – Trends in bioinformatics dealmaking 

 

2.1. Introduction 

2.2. Bioinformatics partnering over the years 

2.3. Big pharma bioinformatics dealmaking activity 

2.4. Big Biotech bioinformatics dealmaking activity 

2.5. Most active bioinformatics dealmakers 

2.6. Bioinformatics partnering by deal type 

2.7. Bioinformatics partnering by stage of development 

2.8. Bioinformatics partnering by disease type 

2.9. Average deal terms for bioinformatics partnering 

2.9.1 Bioinformatics partnering headline values 

2.9.2 Bioinformatics deal upfront payments 

2.9.3 Bioinformatics deal milestone payments 

2.9.4 Bioinformatics royalty rates 

  

Chapter 3 – Leading bioinformatics deals 

  

3.1. Introduction 

3.2. Top bioinformatics deals by value 

3.3. Top bioinformatics deals involving big pharma 

  

Chapter 4 – Bigpharma bioinformatics deals 

  

4.1. Introduction 

4.2. How to use bigpharma bioinformatics partnering deals 

4.3. Big pharma bioinformatics partnering company profiles 

Abbott 

Allergan 

Amgen 

Astellas 

AstraZeneca 

Baxter International 

Bayer 

Biogen Idec 

Boehringer Ingelheim 

Bristol-Myers Squibb 

CSL 

Daiichi Sankyo 

Dainippon Sumitomo 

Eisai 

Eli Lilly 

Galderma 

GlaxoSmithKline 

Grifols 

Hospira 

Johnson & Johnson 

Lundbeck 

Merck & Co 

Merck KGaA 

Mitsubishi Tanabe 

Novartis 

Novo Nordisk 

Otsuka 

Pfizer 

Purdue 

Roche 

Sanofi 

Servier 

Shire 

Takeda 

Teva 

UCB 

Valeant 

  

Chapter 5 – Bigbiotech bioinformatics deals 

5.1. Introduction 

5.2. How to use big biotech partnering deals 

5.3. Big biotech bioinformatics partnering company profiles 

Array Biopharma 

Dendreon 

Elan 

Galapagos 

Genmab 

Grifols 

Ipsen 

Novo Nordisk 

Onyx Pharmaceuticals 

Spectrum Pharmaceuticals 

Vertex Pharmaceuticals 

  

Chapter 6 – Bioinformatics dealmaking directory with contracts 

  

6.1. Introduction 

6.2. By stage of development 

Discovery 

Formulation 

Marketed 

Phase III 

6.3. By deal type 

Asset purchase 

Bigpharma outlicensing 

Collaborative R&D 

Co-market 

Contract service 

Co-promotion 

Development 

Distribution 

Equity purchase 

Licensing 

Litigation 

Manufacturing 

Marketing 

Option 

Promotion 

Research 

Settlement 

Sub-license 

Supply 

Termination 

6.4. By therapy area 

Cardiovascular 

Hematology 

Hospital care 

Infectives 

Oncology 

  

Chapter 7 – Bioinformatics dealmaking by technology type 

Bioinformatics 

Software tools 

  

Chapter 8 – Partnering resource center 

8.1. Online partnering 

8.2. Partnering events 

8.3. Further reading on dealmaking 

About Wildwood Ventures 

Current Partnering 

Current Agreements 

Recent report titles from Current Partnering 

Order Form – Reports 

  

  

Appendices 

  

Appendix 1: By company A-Z 

Appendix 2: By stage of development 

Appendix 3: By deal type 

Appendix 4: By therapy area 

  

  

Table of figures 

  

Figure 1: Bioinformatics partnering since 2007 

Figure 2: Big pharma – top 50 – bioinformatics deals 2007 to 2013 

Figure 3: Big pharma biomarker deal frequency – 2007 to 2013 

Figure 4: Big biotech – top 50 – bioinformatics deals 2007 to 2013 

Figure 5: Big biotech biomarker deal frequency – 2007 to 2013 

Figure 6: Active bioinformatics dealmaking activity– 2007 to 2013 

Figure 4: Bioinformatics partnering by deal type since 2007 

Figure 5: Bioinformatics partnering by deal type since 2007 

Figure 6: Bioinformatics partnering by disease type since 2007 

Figure 10: Bioinformatics deals with a headline value – by stage of development 

Figure 11: Bioinformatics deal headline value distribution – discovery stage, US$million 

Figure 12: Bioinformatics deal headline value distribution – preclinical stage, US$million 

Figure 13: Bioinformatics deal headline value distribution – phase I stage, US$million 

Figure 14: Bioinformatics deal headline value distribution – phase II stage, US$million 

Figure 15: Bioinformatics deal headline value distribution – phase III stage, US$million 

Figure 16: Bioinformatics deal headline value distribution – regulatory stage, US$million 

Figure 17: Bioinformatics deal headline value distribution – marketed stage, US$million 

Figure 18: Summary median headline value by stage of development, 2007-2013 

Figure 19: Bioinformatics deals with upfront payment values – by stage of development 

Figure 20: Bioinformatics deal upfront payment distribution – discovery stage, US$million 

Figure 21: Bioinformatics deal upfront payment distribution – preclinical stage, US$million 

Figure 22: Bioinformatics deal upfront payment distribution – phase I stage, US$million 

Figure 23: Bioinformatics deal upfront payment distribution – phase II stage, US$million 

Figure 24: Bioinformatics deal upfront payment distribution – phase III stage, US$million 

Figure 25: Bioinformatics deal upfront payment distribution – regulatory stage, US$million 

Figure 26: Bioinformatics deal upfront payment distribution – phase marketed stage, US$million 

Figure 27: Summary median upfront value by stage of development, 2007-2013 

Figure 28: Bioinformatics deals with milestone payments – by stage of development 

Figure 29: Bioinformatics deal milestone value distribution, US$million – discovery stage 

Figure 30: Bioinformatics deal milestone value distribution, US$million – preclinical stage 

Figure 31: Bioinformatics deal milestone value distribution, US$million – phase I stage 

Figure 32: Bioinformatics deal milestone value distribution, US$million – phase II stage 

Figure 33: Bioinformatics deal milestone value distribution, US$million – phase III stage 

Figure 34: Bioinformatics deal milestone value distribution, US$million – regulatory stage 

Figure 35: Bioinformatics deal milestone value distribution, US$million – marketed stage 

Figure 36: Bioinformatics deals with royalty rates- by stage of development 

Figure 37: Bioinformatics deal royalty rates value distribution, US$million – discovery stage 

Figure 38: Bioinformatics deal royalty rates value distribution, US$million – preclinical stage 

Figure 39: Bioinformatics deal royalty rates value distribution, US$million – phase I stage 

Figure 40: Bioinformatics deal royalty rates value distribution, US$million – phase II stage 

Figure 41: Bioinformatics deal royalty rates value distribution, US$million – phase III stage 

Figure 42: Bioinformatics deal royalty rates value distribution, US$million – regulatory stage 

Figure 43: Bioinformatics deal royalty rates value distribution, US$million – marketed stage 

Figure 44: Summary median milestone value by stage of development, 2007-2013 

Figure 45: Top bioinformatics deals by value since 2007 

Figure 46: Top bioinformatics deals signed by big pharma value since 2007 

Figure 47: Online partnering resources 

Figure 48: Forthcoming partnering events